Editas Medicine, Inc. Aktie News

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update.

Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is...

Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)

Editas Medicine just successfully navigated a key regulatory issue. Its reni-cel candidate now has a clearer path through its clinical trials.

Editas Medicine, Inc. (NASDAQ:EDIT ) TD Cowen 44th Annual Healthcare Conference March 4, 2024 12:50 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good afternoon and welcome once again to TD Cowen's 44th Annual Healthcare Conference. I'm Phil Nadeau, one of Cowen's biotech analysts, and it's my pleasure to mode...

Editas Medicine has recorded solid progress with its leading candidate. The biotech's financial position looks strong, given its clinical-stage status.